Related Experiment Video
Updated: Jul 16, 2025

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
Published on: May 18, 2017
Mitochondria-derived Vesicle Packaging as a Novel Therapeutic Mechanism in Pulmonary Hypertension
Qiang Zhao1,2, Zhixue Liu1, Ping Song1
1Center for Molecular and Translational Medicine, Georgia State University, Atlanta, Georgia; and.
Abstract:
Increasing evidence suggests that mitochondrial dysfunction in pulmonary endothelial cells (ECs) plays a causative role in the initiation and progression of pulmonary hypertension (PH); how mitochondria become dysfunctional in PH remains elusive. Mitochondria-derived vesicles (MDVs) are small subcellular vesicles that excise from mitochondria. Whether MDV deregulation causes mitochondrial dysfunction in PH is unknown. The aim of this study was to determine MDV regulation in ECs and to elucidate how MDV deregulation in ECs leads to PH. MDV formation and mitochondrial morphology/dynamics were examined in ECs of EC-specific liver kinase B1 (LKB1) knockout mice (LKB1ec-/-), in monocrotaline-induced PH rats, and in lungs of patients with PH. Pulmonary ECs of patients with PH and hypoxia-treated pulmonary ECs exhibited increased mitochondrial fragmentation and disorganized mitochondrial ultrastructure characterized by electron lucent-swelling matrix compartments and concentric layering of the cristae network, together with defective MDV shedding. MDVs actively regulated mitochondrial membrane dynamics and mitochondrial ultrastructure via removing mitofission-related cargoes. The shedding of MDVs from parental mitochondria required LKB1-mediated mitochondrial recruitment of Rab9 GTPase. LKB1ec-/- mice spontaneously developed PH with decreased mitochondrial pools of Rab9 GTPase, defective MDV shedding, and disequilibrium of the mitochondrial fusion-fission cycle in pulmonary ECs. Aerosol intratracheal delivery of adeno-associated virus LKB1 reversed PH, together with improved MDV shedding and mitochondrial function in rats in vivo. We conclude that LKB1 regulates MDV shedding and mitochondrial dynamics in pulmonary ECs by enhancing mitochondrial recruitment of Rab9 GTPase. Defects of LKB1-mediated MDV shedding from parental mitochondria instigate EC dysfunction and PH.
Insights
Defects in mitochondria-derived vesicles (MDVs) shedding, regulated by liver kinase B1 (LKB1), cause pulmonary hypertension (PH) by impairing mitochondrial function in pulmonary endothelial cells (ECs). Restoring LKB1 function reversed PH in rats.
Area of Science:
- Mitochondrial Biology
- Cellular Physiology
- Vascular Biology
Background:
- Mitochondrial dysfunction in pulmonary endothelial cells (ECs) is implicated in pulmonary hypertension (PH).
- The precise mechanisms leading to mitochondrial dysfunction in PH remain unclear.
- Mitochondria-derived vesicles (MDVs) are involved in mitochondrial quality control, but their role in PH is unknown.
Purpose of the Study:
- To investigate the regulation of MDV shedding in pulmonary ECs.
- To determine if MDV deregulation contributes to mitochondrial dysfunction and PH.
- To elucidate the role of liver kinase B1 (LKB1) in MDV shedding and PH pathogenesis.
Main Methods:
- Examined MDV formation and mitochondrial morphology/dynamics in LKB1-deficient ECs, PH rat models, and human PH lung tissues.
- Assessed mitochondrial ultrastructure, MDV shedding, and Rab9 GTPase localization.
- Utilized adeno-associated virus (AAV)-LKB1 gene therapy in a rat model of PH.
Main Results:
- Pulmonary ECs from PH patients and hypoxia-treated cells showed increased mitochondrial fragmentation and defective MDV shedding.
- LKB1 deficiency in ECs led to spontaneous PH, impaired MDV shedding, and disrupted mitochondrial dynamics.
- LKB1-mediated recruitment of Rab9 GTPase to mitochondria is essential for MDV shedding.
- AAV-LKB1 treatment reversed PH in rats, improving MDV shedding and mitochondrial function.
Conclusions:
- LKB1 regulates MDV shedding from pulmonary ECs by promoting Rab9 GTPase mitochondrial recruitment.
- Defective LKB1-mediated MDV shedding contributes to EC dysfunction and PH development.
- Targeting LKB1-MDV pathway may offer a therapeutic strategy for PH.
More Related Videos
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
08:08Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...